Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cáncer;Detección y características de células prostáticas circulantes primarias, asociación con la presencia de micrometástasis y las implicaciones para el tratamiento quirúrgico en hombres con cáncer prostático

Archivos Espanoles de Urologia

Volumn 63, Issue 5, 2010, Pages 345-353

  Murray, Nigel P ^a,b,c   Reyes, Eduardo ^e   Badínez, Leonardo ^d   Orellana, Nelson ^a   Dueñas, Ricardo ^a   Fuentealba, Cinthia ^e  

^a Department of Oral and Maxillofacial Surgery   (Spain)

^b Instituto de BioOncología   (Spain)

^c UNIVERSIDAD MAYOR   (Chile)

^d Fundación Arturo López Pérez   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

CD82; Circulating tumor cells; Micrometastasis; Prostate cancer

Indexed keywords

AGED; ARTICLE; HUMAN; MALE; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; TUMOR EMBOLISM;

AGED; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS;

EID: 77957850070     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: Update. J Urol 1994;143:358-64.
2. Mettlin CJ, Jones GW, Murphy GP. Trends in prostate cancer care in the United States. 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83-91.
3. Lu-Yao G, McLerran D, Wasson J, Wennberg JE. An assessment of radical pprostatectomy. Time trends, geographic variation and outcomes. The prostate patient outcomes research team. JAMA 1993;269:633-6.
4. Epstein JL, Pizov G, Walsh PC. Correlation of pathologic findings and progression after radical prostatectomy: facts and open questions. Eur Urol 1997;32:41-7.
5. Bosch SCH, Schroeder FH. Current problems in staging and grading prostatic carcinoma with special reference to T3 carcinoma of the prostate. World J Urol 1986;4:141-6.
6. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996;48:80-90. (Pubitemid 26255964)
7. van den Ouden D, Davidson PJRT, Hop W, Schroeder FH. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1996;151:646-51.
8. Partin A, Yoo J, Carter HB, Pearson D, Chan DW, Epstein JL, Walsh PC. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4. (Pubitemid 24350837)
9. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2.650-8. (Pubitemid 23147702)
10. Murray NP. El uso de doble-inmunomarcación para detectar células prostáticas en la circulación sanguínea (CPCs) en pacientes con cáncer prostático y las correlaciones con los parámetros clínicos. Rev Chil Urol 2006;71:135-40.
11. Murray NP, Badinez L. Las células prostáticas en la circulación sanguínea en pacientes con cáncer prostático expresan la proteína P504S: un estudio utilizando inmunocitoquímica. Rev Chil Urol 2008;73:54-7.
12. Murray NP. La expresión HER-2 en células prostáticas en la circulación sanguínea (CPCs) y el efecto del tratamiento con la supresión androgéncia en pacientes con cáncer de la próstata. Rev Chil Urol 2007;72:190-4.
13. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Issacs WB et al. Down regulation of the KaI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56:4387-90. (Pubitemid 26330445)
14. Lijovic M, Somers G, Frauman AG. KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer. Cancer Detect Prev 2002;26:69-77. (Pubitemid 36087185)
15. Jackson P, Ow K, Yardley G, Delprado W, Quinn DI, Yang JI et al. Downregulation of KAI1 mRNA in localized prostate cancer and its bony metastasis does not correlate with p53 overexpression. Prostate Cancer prostatic Dis 2003;6:174-81. (Pubitemid 36798388)
16. Borgen E, Naume B, Nesland JM, Kvalhein E, Beiske K, Fodsted O et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;5:377-88.
17. Murray NP, Calaf GM, Badinez L. Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients. Oncol Reports 2009;21:571-5.
18. Katz AE, De Vries GM, Benson MC, Buttyan RE, O'Toole K, Ruben MA et al. The role of the reverse transcriptase polymerase chain reaction assay for PSA in the selection of patients for radical prostatectomy. Urol Clin North Am 1996;23:541-9. (Pubitemid 27000021)
19. Witjes WP, Sculman CC, Debruyne FM. Preliminary results of a prospective study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urol 1997;49(3A Suppl) 65-9.
20. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS. Positive surgical margins at radical prostatectomy: importance of apical dissection. J Urol 1990;143:166-72.